MD&A · 2025
In this section4 topics
Overview of Operations
Overview of Operations
In 2025, the overall Thai economy tended to slow down in line with general economic conditions, resulting in increased price competition within the private hospital industry. However, the Company had already prepared contingency plans for such situations, enabling smooth operations amidst changes and maintaining continuous growth in performance results. Despite the economic slowdown, the Company successfully managed and drove business growth, partly due to the execution of its core strategy focusing on high-intensity medical expertise, which is a key strength of the hospital. Another part involved strategic adjustments to changing situations by marketing to new countries with high demand for complex medical treatments and strong purchasing power, to diversify risks from existing customer groups who might be affected by economic conditions. The Company achieved its strategic goals, resulting in strong growth in revenue from Inpatients (IPD) and international patients requiring specialized and complex treatments.
Regarding the overall international customer base, although Chinese tourist numbers declined in line with market conditions, the Company continued to gain trust from Chinese expatriates living in Thailand, who utilized services consistently. Meanwhile, the core customer group from neighboring countries, particularly patients from Myanmar, maintained a healthy growth rate driven by treatments for complex diseases. Furthermore, the expansion into the Middle Eastern (Arab) market was successful, achieving high growth to become the largest portion of international patient revenue, reflecting the effectiveness and concrete success of the international market expansion strategy.
Regarding external factors, such as policy changes by health insurance companies concerning co-payment conditions, it is assessed to have only a minimal impact on the Company. On the contrary, the Company sees a positive opportunity from this situation, as customers are more likely to choose healthcare providers that offer better value and cost-effectiveness, which aligns with the service positioning of Praram 9 Hospital.
Consequently, the Company continues to strictly follow its strategic plans while preparing contingency plans to handle all forms of economic and industry volatility, ensuring that the Company can overcome challenges and maintain sustainable growth potential.
Summary of Key Events and Developments
In 2025, the Company executed strategic plans to enhance medical capabilities, integrate technology and innovation into services, and ensure transparent management with a focus on sustainability. This resulted in significant developments and several national and international awards as follows:
1). Medical, Innovation & Service Developments
The Company has continuously advanced its medical treatment capabilities and service provision throughout the year as follows:
Q1: Focused on driving strategy through the 5 Centers of Excellence to effectively increase capacity for complex disease patients.
Q2: Proceeded with marketing and promoting the Wound Care Center and Sex Affirmation Surgery to meet the growing demand of niche markets.
Invested in the latest MRI 3 Tesla technology, opened a new Pain Management & Rehabilitation Center, and renovated the Central Sterile Supply Department (CSSD) to elevate safety standards and operational efficiency.
Q4: Reinforced leadership in orthopedics by launching the "PR9 Robotic Knee Arthroplasty Training Center."
Corporate Innovation: Driven towards full Digital Transformation through the "9 SMART" project to develop innovative services that provide convenience and enhance customer experience.
2). Awards & Recognitions
Driven by operational commitment, in 2025, the Company received international awards and standard certifications across various dimensions, including:
Corporate, Management & Investor Relations
IAA Awards for Listed Companies 2025: Received Best Executive awards in 3 categories: Outstanding CEO, Outstanding CFO, and Outstanding IR from the Investment Analysts Association.
SET Awards 2025: Received Outstanding Investor Relations Awards.
Thailand’s Most Admired Company 2025-2026 by BrandAge Magazine: Ranked No. 1 for "Most Trusted Corporate Image" (Corporate Image Score: 8.23) and ranked 3rd in the private hospital industry (Overall average score: 7.23).
Medical Excellence & International Recognition
World's Best Hospitals 2025 (by Newsweek & Statista): Ranked among the Top 10 in Thailand (9th place with a score of 75.40%).
Asia's Top Private Hospitals 2025 (Newsweek & Statista): Recognized for expertise in Asia in 3 areas: Knee Surgery & Knee Replacement, Cataract Surgery, and Refractive Eye Surgery.
Best Specialized Hospitals Asia Pacific 2024 (Newsweek & Statista): Ranked No. 1 in Thailand as a specialized orthopedic hospital and 33rd in the Asia-Pacific region.
Bangkok Life Hospital Awards 2025: Received the Excellence in Medical Management Award and Healthcare Utilization Award.
Sustainability & ESG
SET ESG Ratings 2023-2025: Evaluated at the "AAA" level, the highest rating, for the third consecutive year.
SET Awards 2025: Received the Commended Sustainability Awards.
Innovation & Marketing
Future Trends Awards 2026: Received "The Most Transformational" (The Winner of Tomorrow) award, reflecting the corporate image ready for future changes.
MAAT Media Awards 2025: Received GOLD AWARD for Best Use of OOH and Transit for the success of the innovative "The Eye-Diagnostic Billboard" campaign.
Operating Results & Financial Condition
Operating Results & Profitability
Summary of operating results
In 2025, Praram 9 Hospital maintained strong and continuous growth in performance results, both in revenue and net profit. This success was driven by strategic initiatives significantly expanding the international patient base, particularly from the Middle East, who showed increasing demand for specialized medical services and complex treatments.
In 2025, hospital operation revenue continued to grow, supported by the increase in both patient volume and average revenue per treatment, resulting from the focus on high-intensity complex disease patients. This aligned with the significant expansion of the international patient base. Consequently, in 2025, the Company's total revenue reached Baht 5,341.4 million, a 13.9% increase from Baht 4,690.5 million in 2024. Net profit for the year was Baht 822.7 million, or 15.4% of total revenue, a 15.4% increase from Baht 712.7 million (15.2% net profit margin) in the previous year. This outstanding profit growth also reflects efficiency in operational cost management and optimization of internal resources.
Revenue
(1) Revenue from Medical Services
In 2025, the hospital's medical service revenue was Baht 5,276.6 million, an increase of 13.8% from Baht 4,635.4 million in 2024. As a proportion of total revenue, hospital operation revenue accounted for 98.8% in both 2025 and 2024.
Medical service revenue classified by service type is detailed as follows:
Medical Services Revenue By Service Type | For the year ended 31 December | |||||
2025 | 2024 | Change | ||||
Million Baht | % | Million Baht | % | Million Baht | % | |
Outpatient (OPD) Revenue | 2,862.0 | 54.2 | 2,731.1 | 58.9 | +130.9 | +4.8 |
Inpatient (IPD) Revenue | 2,414.6 | 45.8 | 1,904.3 | 41.1 | +510.3 | +26.6 |
Total hospital revenue | 5,276.6 | 100.0 | 4,635.4 | 100.0 | +641.2 | +13.8 |
Hospital Revenue Portion of Total Revenue | 98.8 | 98.8 | ||||
Outpatient (OPD) revenue increased by 4.8% YoY, driven by both patient volume (No. of visits) and average revenue per visit. Inpatient (IPD) revenue grew by 26.8% YoY, resulting from an increase in patient days and revenue per patient day due to more complex medical treatments.
Medical service revenue classified by patient nationality is detailed as follows:
Medical Service Revenue by Nationality | For the year ended 31 December | |||||
2025 | 2024 | Change | ||||
Million Baht | % | Million Baht | % | Million Baht | % | |
Revenue from Thai Patients | 3,916.2 | 74.0 | 3,849.2 | 83.0 | +67.0 | +1.7 |
Revenue from International Patients | 1,360.3 | 26.0 | 786.2 | 17.0 | +574.1 | +73.0 |
Total revenues from Hospital Operations | 5,276.6 | 100 | 4,635.4 | 100 | +641.2 | +13.8 |
Hospital Revenue Portion of Total Revenue | 98.8 | 98.8 | ||||
Revenue from Thai patients increased by 1.7% YoY, while revenue from international patients surged by 73.0% YoY. This significant growth increased the international patient revenue portion to 26% of total hospital revenue (up from 17% in 2024), primarily driven by Fly-in patients from the Middle East and market expansion into international insurance holders.
Medical service revenue classified by payment type is detailed as follows:
Medical Service Revenue by Payment Type | For the year ended 31 December | |||||
2025 | 2024 | Change | ||||
Million Baht | % | Million Baht | % | Million Baht | % | |
Self-Pay Customers | 3,196.2 | 61.0 | 3,064.3 | 66.0 | +130.9 | +4.8 |
Insurance Customers | 1,272.7 | 24.0 | 1,237.0 | 27.0 | +35.7 | +2.9 |
Contract Customers | 807.7 | 15.0 | 334.1 | 7.0 | +473.6 | +141.8 |
Total revenues from Hospital Operations | 5,276.6 | 100 | 4,635.4 | 100 | +641.2 | +13.8 |
Hospital Revenue Portion of Total Revenue | 98.8 | 98.8 | ||||
Revenue from contract companies showed remarkable growth of 141.8% YoY, following the success in expanding the Fly-in patient base from the Middle East and international insurance holders, most of whom utilize contract-based payments. Meanwhile, revenue from self-pay and health insurance groups continued to grow at 4.3% and 2.9% respectively, supported by proactive PR and collaboration projects with insurance companies and partners to effectively expand the Thai customer base.
(2) Other income
Other income | Unit | For the year ended 31 December | |||
2025 | 2024 | Change | |||
Million Baht | % | ||||
Rental Revenues | Million Baht | 15.7 | 13.6 | +2.1 | +15.1 |
Other revenues | Million Baht | 49.1 | 41.5 | +7.6 | +18.4 |
Total other income | Million Baht | 64.8 | 55.1 | +9.7 | +17.6 |
% of Total revenues | % | 1.2 | 1.2 | ||
Other income includes non-medical service revenue such as shop rentals, service fees, nursing dormitory rentals, dividends, and gains from securities investments. In 2025, other income was Baht 64.8 million (1.2% of total revenue), compared to Baht 55.1 million (1.2% of total revenue) in 2024.
Expenses
The principal expenses of the hospital consist of the Cost of Hospital Operations and Selling and Administrative Expenses.
Expenses | Unit | For the year ended 31 December | |||
2025 | 2024 | Change | |||
Million Baht | % | ||||
Cost of Hospital Operations | Million Baht | 3,346.3 | 3,045.4 | +300.8 | +9.9 |
% of Hospital Revenue | % | 63.4 | 65.7 | ||
Selling Expenses | Million Baht | 270.1 | 158.0 | +112.1 | +70.9 |
Administrative Expenses | Million Baht | 762.4 | 679.2 | +83.2 | +12.2 |
Total Selling and Administrative Expenses | Million Baht | 1,032.5 | 837.2 | +195.3 | +23.3 |
% of Total Revenue | % | 19.3 | 17.8 | ||
Total Expenses | Million Baht | 4,378.8 | 3,882.7 | +496.1 | +12.8 |
% of Total Revenue | % | 82.0 | 82.8 | ||
(1) Cost of hospital operations
In 2025, the Company reported cost of hospital operations (including depreciation and amortization) of Baht 3,346.3 million, or 63.4% of hospital revenue, compared to Baht 3,045.4 million or 65.7% in 2024. The decrease in cost proportion resulted from process improvements leading to efficiency and cost reduction, alongside increased economies of scale as fixed costs were spread over higher revenue.
(2) Selling and administrative expenses
Selling and administrative expenses (including depreciation and amortization) in 2025 were Baht 1,032.5 million, or 19.3% of total revenue, compared to Baht 837.2 million (17.8%) in 2024. The increase primarily came from marketing and PR expenses to build brand awareness locally and internationally, aligning with the international expansion strategy. Additionally, expenses increased due to adjustments in employee benefit provisions—the Company rewards long-term employees with gold ornaments, the price of which increased significantly—and the write-off of assets with remaining book value to expand and renovate service areas for future use.
Profit and profit margin
Profit and Profit Margin | Unit | For the year ended 31 December | |||
2025 | 2024 | Change | |||
Million Baht | % | ||||
Operating profit | Million Baht | 962.7 | 807.9 | +154.8 | +19.2 |
Total Depreciation and Amortization | Million Baht | 313.3 | 306.4 | +6.9 | +2.2 |
EBITDA | Million Baht | 1,275.9 | 1,114.3 | +161.6 | +14.5 |
% of Total Revenue | % | 23.9 | 23.8 | ||
Financial income | Million Baht | 51.3 | 54.6 | -3.3 | -6.0 |
Financial costs | Million Baht | 0.8 | 0.5 | +0.3 | +55.4 |
Income tax expense | Million Baht | 190.5 | 149.3 | +41.2 | +27.6 |
Profit for the year | Million Baht | 822.7 | 712.7 | +110.0 | +15.4 |
Net Profit Margin | % | 15.4 | 15.2 | ||
In 2025, the Company reported EBITDA Baht 1,275.9 million, an EBITDA margin of 23.9% (compared to Baht 1,114.3 million or 23.8% in 2024).
Financial income decreased from 2024 due to the government's announcement of interest rate cuts to stimulate the economy. Financial costs of Baht 0.8 million increased by 55.4% from the same period of the previous year. This was primarily due to an increase in the number of lease agreements under TFRS 16, resulting in the recognition of interest from lease liabilities as financial costs. However, the Company has no interest obligations from other loan liabilities.
The Company reported a profit for the year 2025 of Baht 822.7 million, representing a net profit margin of 15.4%, a 15.4% increase from the profit for the year 2024 of Baht 712.7 million (net profit margin of 15.2%). Basic earnings per share were 1.05 Baht per share, compared to 0.91 Baht per share in 2024, respectively.
Liquidity & Capital Adequacy
Cash Flow
Sources and uses of cash flow by categories are summarized below.
Cash Flow Statement (Million Baht) | For the year ended December 31 | ||
2025 | 2024 | Change | |
Net cash from operating activities | 988.7 | 1,039.9 | -51.1 |
Net cash used in investing activities | (364.1) | (2,038.2) | -1,674.1 |
Net cash used in financing activities | (359.0) | (357.7) | +1.3 |
Net increase (decrease) in cash and cash equivalents | 265.7 | (1,356.1) | -1,090.4 |
Cash and cash equivalents, beginning of year | 394.8 | 1,750.9 | -1,356.1 |
Cash and cash equivalents, end of year | 660.5 | 394.8 | +265.7 |
Analysis of Liquidity and Sources of Funds
(1) Cash flow from operating activities
In 2025, net cash from operating activities was Baht 988.7 million, a decrease of Baht 51.1 million from Baht 1,039.9 million in 2024, due to an increase in trade and other receivables.
(2) Cash flow from investing activities
For the year 2025, the Company had net cash used in investing activities of Baht 364.1 million, consisting of cash paid for purchasing assets and settling outstanding payables from asset purchases during the period of Baht 529.0 million, net of the redemption of matured investments of Baht 106.7 million and interest received of Baht 58.2 million (compared to net cash used in investing activities of Baht 2,038.2 million in 2024).
(3) Cash flow from financing activities
For the year 2025, the Company had net cash used in financing activities of Baht 359.0 million, mainly from dividend payments and repayment of the principal portion of lease liabilities, compared to Baht 357.7 million used in the 2024 period.
Cash and cash equivalents
The Company had cash and cash equivalents as of 31 December 2025, of Baht 660.5 million, an increase of Baht 265.7 million from Baht 394.8 million, primarily due to debt instrument investments maturing at the end of the year, which are currently pending reinvestment.
Asset Management Capability
Summary of Financial Position
Statement of Financial Position (Million Baht) | As of 31 December 2025 | As of 31 December 2024 | Change (%) |
Total Current Assets | 3,362.5 | 2,657.5 | +26.5 |
Total Non-Current Assets | 3,664.8 | 3,741.6 | -2.1 |
Total Assets | 7,027.3 | 6,399.1 | +9.8 |
Total Current Liabilities | 880.1 | 757.7 | +16.1 |
Total Non-Current Liabilities | 271.7 | 202.8 | +33.9 |
Total Liabilities | 1,151.8 | 960.5 | +19.9 |
Total Shareholders' Equity | 5,875.5 | 5,438.5 | +8.0 |
Total Liabilities and Shareholders' Equity | 7,027.3 | 6,399.1 | +9.8 |
As of 31 December 2025, total assets were Baht 7,027.3 million, a 9.8% increase from 2024, primarily driven by the increase in current financial assets from investing cash flow into open-end funds for liquidity management.
Total liabilities were Baht 1,151.8 million, a 19.9% increase, resulting from higher trade payables for medical supplies to support increased patient volume and employee benefit provisions. Total shareholders' equity was Baht 5,875.5 million, an 8.0% increase, growing from total comprehensive income for the year net of dividends paid.
Financial Position Analysis
Total Assets
The Company's total assets are divided into two main groups, comprising::
(1) Current assets, including cash and cash equivalents, trade and other receivables, medicines, medical supplies and inventories, and other current financial assets, etc.
(2) Non-current assets, including property, plant and equipment, intangible assets, and other non-current financial assets, etc.
As of 31 December 2025, current assets were Baht 3,362.5 million, a 26.5% increase from Baht 2,657.5 million in 2024. The increase was mainly in current financial assets from investing surplus cash into open-end funds to provide flexibility in cash management during declining interest rate conditions.
As of 31 December 2025, the hospital had non-current assets of Baht 3,664.8 million, a decrease of 2.1% from Baht 3,741.6 million as of 31 December 2024, due to a reduction in long-term fixed bank deposits resulting from declining interest rates, to be invested in more flexible open-end mutual funds.
Total Liabilities
The main components of the hospital's total liabilities are trade and other payables, and provision for long-term employee benefits.
As of 31 December 2025, current liabilities were Baht 880.1 million, a 16.1% increase from Baht 757.7 million, due to higher trade and other current payables from increased purchasing to support higher revenue and service volume. As of 31 December 2025, the hospital had non-current liabilities of Baht 271.7 million, an increase of 33.9% from non-current liabilities of Baht 202.8 million. This increase was primarily due to the provision for employee benefits, which is calculated based on actuarial principles.
Total Shareholders' Equity
As of 31 December 2025, the hospital's shareholders' equity was Baht 5,875.5 million, an increase of 8.0% from Baht 5,438.5 million as of 31 December 2024. The increase was driven by the total comprehensive income for the year 2025 of Baht 790.8 million, net of dividend payments of Baht 353.8 million.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
No
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
Significant Factors or Events that may affect Financial Position or Operations in the Future
1. Environmental, Social, and Governance (ESG) Factors, Trends, and Impacts
Facing challenging environmental and social changes, Praram 9 Hospital has planned and implemented comprehensive ESG measures to ensure operational sustainability. Investing in technology and innovation for service efficiency, along with preparing for carbon taxes and new financial reporting standards, helps the hospital lead the market and meet customer needs efficiently and transparently. Key sustainability issues are integrated into strategic planning and risk assessment, with targets set for carbon neutrality and net-zero greenhouse gas emissions by 2065.
2. Factors that may affect Financial Position
1. Carbon Tax Collection: The implementation of carbon tax collection guidelines may cause companies with high greenhouse gas emissions to face increased costs, affecting their profits and operational processes in the long term. Therefore, the Company needs to adjust its strategies to reduce emissions and enhance energy efficiency.
2. Financial Standards IFRS S1 and IFRS S2: The adoption of financial standards IFRS S1 (General Requirements for Disclosure of Sustainability-related Financial Information) and IFRS S2 (Climate-related Disclosures) will increase transparency in financial reporting and the disclosure of sustainability data and climate change risks.
This may require the Company to improve its ESG data measurement and reporting systems, as well as the assessment of financial risks and opportunities related to environmental and social issues.
Overall, these two factors will impact the Company's financial position and operations in the future, requiring the Company to adapt its strategies and internal management systems to accommodate the new standards and effectively and sustainably mitigate the impacts of policy changes and the external environment.
3. Sustainability Developments
Over the past year, the Company has continuously advanced its sustainability operations by integrating Environmental, Social, and Governance (ESG) issues into the corporate strategy to support stable growth and create value for all stakeholder groups.
Environmental
The Company prioritizes efficient energy and resource management and has developed a greenhouse gas emission data collection system (Scope 1–3) as a baseline for long-term carbon reduction targets. Additionally, measures are in place for medical waste reduction, proper waste sorting, and campaigns to reduce single-use plastics, with continuous employee engagement in green corporate activities.
Social
The Company focuses on personnel development through reskilling and upskilling to meet medical technology changes and patient behavior, while building employee engagement and motivation to enhance service quality and patient experience. Furthermore, regular social and community activities are conducted, such as health promotion projects, disease prevention education, and support for public benefit activities.
Governance
The Company operates under good governance principles with tight, transparent, and auditable internal control and risk management systems. The Board of Directors and sub-committees play key roles in overseeing sustainability issues and regularly monitoring progress against set targets.
Through these efforts, the Company shows clear progress in sustainability development to create balanced growth in performance, stakeholder confidence, and long-term environmental responsibility.

